US Patients Seek Cancer Drugs in China

Cancer patients in the United States are increasingly traveling to China to obtain life-saving medications and participate in clinical trials, a trend underscoring China's emergence as a global biotech leader. Debbie Doppelt, a lung cancer patient, exemplifies this, obtaining the drug sunvozertinib from China as it awaited U.S. FDA approval. This situation arises as China's biotech sector accounts for a significant percentage of new global drug testing, with companies like Dizal Pharmaceutical developing innovative therapies.

The United States faces mounting pressure as regulatory processes, particularly those of the FDA, are perceived as slow and prohibitive. This has led many U.S. biotechs to conduct early-stage clinical trials in countries like Australia, Europe, and China, a shift from a decade ago when such trials were predominantly U.S.-based. Operation TrialBlazer was initiated by the Trump administration to expedite FDA processes and retain clinical trials within the U.S.

China's transformation into a biotech powerhouse followed a critical review of its sector after the COVID-19 pandemic. Venture capital now heavily supports early-stage clinical work in China and Australia due to their faster regulatory systems. This rapid progress has also led U.S. biotech CEOs to conceal their advancements from competitors, fearing swift market replication. Concerns about U.S. dependency on Chinese medicines and potential job losses have spurred legislative efforts to scrutinize U.S. pharmaceutical deals with Chinese firms.

While some advocate for protectionism, others argue that China's advancements in medicine are collaborative efforts against common enemies like cancer. The International Cancer Advocacy Network supports pursuing Chinese options when U.S.-approved drugs are unavailable. Despite the U.S. preference for domestic development, collaboration is seen as essential for global health security.